Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Palladino, F. Bahjat, E. Theodorakis, L. Moldawer (2003)
Anti-TNF-alpha therapies: the next generation.Nature reviews. Drug discovery, 2 9
Alicia Higueruelo, A. Schreyer, G. Bickerton, W. Pitt, C. Groom, T. Blundell (2009)
Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL DatabaseChemical Biology & Drug Design, 74
P. Fischer, D. Lane (2004)
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?Trends in pharmacological sciences, 25 7
D. Roman, J. Talbot, R. Roof, R. Sunahara, J. Traynor, R. Neubig (2007)
Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction AssayMolecular Pharmacology, 71
D. Fry (2006)
Protein-protein interactions as targets for small molecule drug discovery.Biopolymers, 84 6
Whitty (2006)
Between a rock and a hard place?Nat. Chem. Biol., 2
B. Raimundo, J. Oslob, A. Braisted, J. Hyde, R. McDowell, M. Randal, Nathan Waal, J. Wilkinson, Chul Yu, M. Arkin (2004)
Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions.Journal of medicinal chemistry, 47 12
P. Hajduk, M. Bures, Jens Praestgaard, S. Fesik (2000)
Privileged molecules for protein binding identified from NMR-based screening.Journal of medicinal chemistry, 43 18
Tabetha Bonacci, Jennifer Mathews, Chujun Yuan, D. Lehmann, S. Malik, Dianqing Wu, Jose Font, J. Bidlack, A. Smrcka (2006)
Differential Targeting of Gßγ-Subunit Signaling with Small MoleculesScience, 312
J. Proudfoot (2002)
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs.Bioorganic & medicinal chemistry letters, 12 12
D. Lehmann, A. Seneviratne, A. Smrcka (2008)
Small Molecule Disruption of G Protein βγ Subunit Signaling Inhibits Neutrophil Chemotaxis and InflammationMolecular Pharmacology, 73
R. Bourgeas, M. Basse, X. Morelli, P. Roche (2010)
Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I DatabasePLoS ONE, 5
B. Leader, Quentin Baca, D. Golan (2008)
Protein therapeutics: a summary and pharmacological classificationNature Reviews Drug Discovery, 7
M. Wendt, Chaohong Sun, Aaron Kunzer, D. Sauer, Kathy Sarris, Ethan Hoff, Liping Yu, D. Nettesheim, Jun Chen, Sha Jin, K. Comess, Yihong Fan, S. Anderson, B. Isaac, E. Olejniczak, P. Hajduk, S. Rosenberg, S. Elmore (2007)
Discovery of a novel small molecule binding site of human survivin.Bioorganic & medicinal chemistry letters, 17 11
A. Kimple, F. Willard, P. Giguère, C. Johnston, V. Mocanu, D. Siderovski (2007)
The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face.Biochimica et biophysica acta, 1774 9
P. Hajduk, J. Huth, Chris Tse (2005)
Predicting protein druggability.Drug discovery today, 10 23-24
M. He, Annemarie Smith, J. Oslob, W. Flanagan, A. Braisted, A. Whitty, M. Cancilla, Jun Wang, A. Lugovskoy, Joshua Yoburn, Amy Fung, G. Farrington, J. Eldredge, E. Day, Leslie Cruz, T. Cachero, Stephan Miller, Jessica Friedman, I. Choong, B. Cunningham (2005)
Small-Molecule Inhibition of TNF-αScience, 310
Tracy Chen, Natasha Kablaoui, Jeremy Little, Sergei Timofeevski, W. Tschantz, Ping Chen, Junli Feng, Maura Charlton, R. Stanton, P. Bauer (2009)
Identification of small-molecule inhibitors of the JIP-JNK interaction.The Biochemical journal, 420 2
D. Lehmann, A. Seneviratne, A. Smrcka (2008)
Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation.Molecular pharmacology, 73 2
A. Hopkins, C. Groom, A. Alex (2004)
Ligand efficiency: a useful metric for lead selection.Drug discovery today, 9 10
Lipinski (1997)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingAdv. Drug Deliv. Rev., 23
Cheol‐Min Park, M. Bruncko, Jessica Adickes, J. Bauch, H. Ding, Aaron Kunzer, K. Marsh, Paul Nimmer, A. Shoemaker, Xiaohong Song, S. Tahir, Chris Tse, Xilu Wang, M. Wendt, Xiufen Yang, Haichao Zhang, S. Fesik, S. Rosenberg, S. Elmore (2008)
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.Journal of medicinal chemistry, 51 21
M. Arkin, J. Wells (2004)
Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 3
S. Paul, D. Mytelka, C. Dunwiddie, Charles Persinger, B. Munos, S. Lindborg, A. Schacht (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 9
O. Sperandio, C. Reynès, A. Camproux, B. Villoutreix (2010)
Rationalizing the chemical space of protein-protein interaction inhibitors.Drug discovery today, 15 5-6
M. Palladino, F. Bahjat, E. Theodorakis, L. Moldawer (2003)
Anti-TNF-α therapies: the next generationNature Reviews Drug Discovery, 2
P. Carter, P. Scherle, Jodi Muckelbauer, M. Voss, Rui-Qin Liu, L. Thompson, A. Tebben, K. Solomon, Yvonne Lo, Zhong Li, P. Strzemienski, Gengjie Yang, Nikoo Falahatpisheh, Meizhong Xu, Zhongren Wu, N. Farrow, K. Ramnarayan, Jing Wang, D. Rideout, V. Yalamoori, P. Domaille, D. Underwood, J. Trzăskos, S. Friedman, R. Newton, C. Decicco (2001)
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-αProceedings of the National Academy of Sciences of the United States of America, 98
A. Bogan, K. Thorn (1998)
Anatomy of hot spots in protein interfaces.Journal of molecular biology, 280 1
M. Arkin, A. Whitty (2009)
The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions.Current opinion in chemical biology, 13 3
P. Dorr, M. Westby, Susan Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, David Price, B. Stammen, A. Wood, M. Perros (2005)
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 ActivityAntimicrobial Agents and Chemotherapy, 49
P. Hajduk (2006)
Fragment-based drug design: how big is too big?Journal of medicinal chemistry, 49 24
J. Wells, Christopher McClendon (2007)
Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 450
Jonathan Fuller, N. Burgoyne, R. Jackson (2009)
Predicting druggable binding sites at the protein-protein interface.Drug discovery today, 14 3-4
D. Fry (2008)
Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry.Current protein & peptide science, 9 3
Alexander Neugebauer, R. Hartmann, C. Klein (2007)
Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods.Journal of medicinal chemistry, 50 19
C. Lipinski, F. Lombardo, B. Dominy, P. Feeney (1997)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 46
S. Sandiford, Qiang Wang, K. Levay, P. Buchwald, V. Slepak (2010)
Molecular organization of the complex between the muscarinic M3 receptor and the regulator of G protein signaling, Gbeta(5)-RGS7.Biochemistry, 49 24
John Overington, B. Al-Lazikani, A. Hopkins (2006)
How many drug targets are there?Nature Reviews Drug Discovery, 5
Levi Blazer, R. Neubig (2009)
Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future HurdlesNeuropsychopharmacology, 34
M. Stumpf, Thomas Thorne, Eric Silva, Ronald Stewart, Hyeong An, M. Lappe, C. Wiuf (2008)
Estimating the size of the human interactomeProceedings of the National Academy of Sciences, 105
Steven Darnell, L. Legault, Julie Mitchell (2008)
KFC Server: interactive forecasting of protein interaction hot spotsNucleic Acids Research, 36
K. Kojima, J. Burks, J. Arts, M. Andreeff (2010)
The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid LeukemiasMolecular Cancer Therapeutics, 9
A. Dömling (2008)
Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?Current opinion in chemical biology, 12 3
G. Suntharalingam, M. Perry, S. Ward, S. Brett, A. Castello-Cortes, Michael Brunner, N. Panoskaltsis (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.The New England journal of medicine, 355 10
E. Margolles-clark, O. Umland, N. Kenyon, C. Ricordi, P. Buchwald (2009)
Small-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interactionJournal of Molecular Medicine, 87
C. Reynolds, S. Bembenek, B. Tounge (2007)
The role of molecular size in ligand efficiency.Bioorganic & medicinal chemistry letters, 17 15
M. Wadman (2006)
London's disastrous drug trial has serious side effects for researchNature, 440
S. Sandiford, Qiang Wang, K. Levay, P. Buchwald, Z. Vladlen, Slepak (2011)
Molecular Organization of the Complex Between Muscarinic M3 Receptor and Regulator of G Protein Signaling Gβ5-RGS7
E. Margolles-clark, Norma Kenyon, C. Ricordi, P. Buchwald (2010)
Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative.Chemical biology & drug design, 76 4
T. Berg (2003)
Modulation of protein-protein interactions with small organic molecules.Angewandte Chemie, 42 22
P. Buchwald (2008)
Glucocorticoid receptor binding: A biphasic dependence on molecular size as revealed by the bilinear LinBiExp modelSteroids, 73
C. Reynès, Hélène Host, A. Camproux, G. Laconde, F. Leroux, A. Mazars, B. Déprez, R. Fåhraeus, B. Villoutreix, O. Sperandio (2010)
Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning MethodsPLoS Computational Biology, 6
As the ultimate function of proteins depends to a great extent on their binding partners, protein–protein interactions (PPIs) represent a treasure trove of possible new therapeutic targets. Unfortunately, interfaces involved in PPIs are not well‐suited for effective small molecule binding. Nevertheless, successful examples of small‐molecule PPI inhibitors (PPIIs) are beginning to accumulate, and the sheer number of PPIs that form the human interactome implies that, despite the relative unsuitability of PPIs to serve as “druggable” targets, small‐molecule PPIIs can still provide novel pharmacological tools and new innovative drugs in at least some areas. Here, after some illustrative examples, accumulating information on the binding efficiency, molecular size, and chemical space requirements will be briefly reviewed. Therapeutic success can only be achieved if these considerations are incorporated into the search process and if careful medicinal chemistry approaches are used to address the absorption, distribution, metabolism, and excretion requirements of larger molecules that are often needed for this target class due to the lower efficiency of binding. © 2010 IUBMB IUBMB Life, 62(10): 724–731, 2010
IUBMB Life – Wiley
Published: Jan 1, 2010
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.